

**Manuscript version: Author's Accepted Manuscript**

The version presented in WRAP is the author's accepted manuscript and may differ from the published version or Version of Record.

**Persistent WRAP URL:**

<http://wrap.warwick.ac.uk/172097>

**How to cite:**

Please refer to published version for the most recent bibliographic citation information. If a published version is known of, the repository item page linked to above, will contain details on accessing it.

**Copyright and reuse:**

The Warwick Research Archive Portal (WRAP) makes this work by researchers of the University of Warwick available open access under the following conditions.

Copyright © and all moral rights to the version of the paper presented here belong to the individual author(s) and/or other copyright owners. To the extent reasonable and practicable the material made available in WRAP has been checked for eligibility before being made available.

Copies of full items can be used for personal research or study, educational, or not-for-profit purposes without prior permission or charge. Provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way.

**Publisher's statement:**

Please refer to the repository item page, publisher's statement section, for further information.

For more information, please contact the WRAP Team at: [wrap@warwick.ac.uk](mailto:wrap@warwick.ac.uk).

1 **Supramolecular Organisation and Dynamics of**  
2 **Mannosylated Phosphatidylinositol Lipids in the Mycobacterial Plasma**  
3 **Membrane**

4 *Chelsea M. Brown*<sup>1</sup>, *Robin A. Corey*<sup>2</sup>, *Axelle Grélard*<sup>3</sup>, *Ya Gao*<sup>4,5</sup>, *Yeol Kyo Choi*<sup>5</sup>, *Emanuel Luna*<sup>5</sup>,  
5 *Martine Gilleron*<sup>6</sup>, *Nicolas Destainville*<sup>7</sup>, *Jérôme Nigou*<sup>6</sup>, *Antoine Loquet*<sup>3</sup>, *Elizabeth Fullam*<sup>1</sup>, *Wonpil*  
6 *Im*<sup>5,\*</sup>, *Phillip J. Stansfeld*<sup>1,8,\*+\*</sup>, *Matthieu Chavent*<sup>6,\*+\*</sup>

7  
8 <sup>1</sup> School of Life Sciences,  
9 University of Warwick,  
10 Coventry,  
11 CV4 7AL,  
12 UK

13  
14 <sup>2</sup> Department of Biochemistry,  
15 University of Oxford,  
16 Oxford,  
17 UK

18  
19 <sup>3</sup> Université de Bordeaux,  
20 CBMN (UMR5248),  
21 CNRS, IPB,  
22 Institut Européen de Chimie et Biologie,  
23 F-33600 Pessac,  
24 France

25  
26 <sup>4</sup> School of Mathematics, Physics and Statistics,  
27 Shanghai University of Engineering Science,  
28 Shanghai 201620,  
29 China

30  
31 <sup>5</sup> Department of Biological Sciences,  
32 Department of Chemistry,  
33 Department of Bioengineering,  
34 Lehigh University,  
35 Pennsylvania 18015,  
36 USA

37  
38 <sup>6</sup> Institut de Pharmacologie et Biologie Structurale (IPBS),  
39 Université de Toulouse, CNRS,  
40 Université Toulouse III – Paul Sabatier,

41 31400, Toulouse,  
42 France

43

44 <sup>7</sup> Laboratoire de Physique Théorique,  
45 Université de Toulouse, CNRS,  
46 UPS, Toulouse,  
47 France

48

49 <sup>8</sup> Department of Chemistry,  
50 University of Warwick,  
51 Coventry,  
52 CV4 7AL,  
53 UK

54

55 + equal contribution

56

57 \*to whom correspondence should be addressed:

58 e-mail: wonpil@lehigh.edu

59 phone: +1 (0) 610-758-4524

60

61 e-mail: phillip.stansfeld@warwick.ac.uk

62 phone: +44 (0) 2476523864

63

64 e-mail: matthieu.chavent@ipbs.fr

65 phone: +33 (0) 5-61-17-59-00

66

67 **Abstract**

68 *Mycobacterium tuberculosis* (*Mtb*) is the causative agent of tuberculosis (TB), a  
69 disease that claims ~1.6 million lives annually. The current treatment regime is long  
70 and expensive, and missed doses contribute to drug resistance. Therefore,  
71 development of new anti-TB drugs remains one of the highest public health priorities.  
72 *Mtb* has evolved a complex cell envelope that represents a formidable barrier to  
73 antibiotics. The *Mtb* cell envelop consists of four distinct layers enriched for *Mtb*  
74 specific lipids and glycans. Although the outer membrane, comprised of mycolic acid  
75 esters, has been extensively studied, less is known about the plasma membrane,  
76 which also plays a critical role in impacting antibiotic efficacy. The *Mtb* plasma  
77 membrane has a unique lipid composition, with mannosylated phosphatidylinositol  
78 lipids (phosphatidyl-*myo*inositol mannosides, PIMs) comprising more than 50% of the  
79 lipids. However, the role of PIMs in the structure and function of the membrane  
80 remains elusive. Here, we used multiscale molecular dynamics (MD) simulations to  
81 understand the structure-function relationship of the PIM lipid family and decipher how  
82 they self-organize to shape the biophysical properties of mycobacterial plasma  
83 membranes. We assess both symmetric and asymmetric assemblies of the *Mtb*  
84 plasma membrane, and compare this with residue distributions of *Mtb* integral  
85 membrane protein structures. To further validate the model, we tested known anti-TB  
86 drugs and demonstrated that our models agree with experimental results. Thus, our  
87 work sheds new light on the organization of the mycobacterial plasma membrane. This  
88 paves the way for future studies on antibiotic development and understanding *Mtb*  
89 membrane protein function.

90

## 91 **Introduction**

92 Tuberculosis (TB) is caused by *Mycobacterium tuberculosis* (*Mtb*). In 2021 alone,  
93 there were an estimated 10.6 million new *Mtb* infections, leading to 1.6 million deaths  
94 (1). Thus, *Mtb* is one of the world's leading infectious killers, despite the availability of  
95 both a treatment regime and vaccine. The current course of antibiotics for drug  
96 susceptible TB cases can last as long as 6 months and consists of four drugs given in  
97 combination (2). This is not only expensive and demanding for the patient, but also  
98 encourages non-compliance that contributes towards the rise in multi-drug resistant  
99 and extremely drug-resistant TB (3). It is obvious that new treatments and a better  
100 vaccine are needed to meet the World Health Organization's 'End TB Strategy'. Their  
101 plan aims to reduce TB-related deaths by 90% by 2030, and thereby curtail the  
102 enormous public health cost caused by TB (4). The COVID-19 pandemic has undone  
103 some of the progress that had been made in the treatment of TB as fewer people were  
104 able to be diagnosed or access medication (5), which might result in a worldwide surge  
105 of untreatable cases. Thus, there is a pressing need for innovative research into the  
106 mechanisms of *Mtb* virulence and its ability to survive within the host for extended  
107 periods to help develop alternative intervention strategies.

108 One issue in anti-TB drug discovery is the complexity of the mycobacterial cell  
109 envelope (6, 7). This cell envelope consists of an array of lipids contributing to both  
110 hydrophobic and polar regions of various thicknesses and densities, making it  
111 extremely challenging to predict how molecules will cross this barrier and enter the  
112 cell. The *Mtb* cell envelope has four distinct layers: the outer layer (or the  
113 *mycomembrane*) comprised of mycolic acid esters and other complex lipids (such as  
114 phthiocerol dimycoserates), an arabinogalactan-peptidoglycan layer, the  
115 periplasmic space and the inner membrane, or the plasma membrane (8). The  
116 mycobacterial plasma membrane plays a key role in controlling nutrient/antibiotic  
117 uptake and contains important membrane proteins that are targets for antitubercular  
118 drugs (9), such as SQ109 that inhibits the transporter MmpL3 (10). The membrane  
119 composition is also known to change during different growth stages of the bacteria (7)  
120 and may modulate drug and membrane protein diffusion. Additionally, recent studies  
121 showed that *Mtb* plasma membrane organization, such as the formation of functional  
122 membrane microdomains (11, 12), can affect the survival ability of mycobacteria.  
123 Therefore, understanding the molecular organization and dynamics of the *Mtb* plasma  
124 membrane is essential for developing effective drug candidates.

125 The mycobacterial plasma membrane is composed of a variety of lipids and  
126 glycolipids, the most abundant being (**Figure 1A**): cardiolipin (CL),  
127 phosphatidylethanolamine (PE), phosphatidyl-*myo*inositol (PI), trehalose  
128 monomycolate (TMM) and phosphatidyl-*myo*inositol mannosides (PIMs) (13), with the  
129 PIMs accounting for over half the dry weight of the plasma membrane lipids (13). PIM<sub>2</sub>  
130 lipids are comprised of a modified PI core decorated with two mannose residues and  
131 one acyl chain (**Figure 1B**). Furthermore, additional modifications of an acyl group  
132 and up to 4 mannose sugars can be added to the core headgroup, further diversifying  
133 the PIM structure (14, 15) (**Figure 1B** and **SI Figure 1**). **It is still unclear if the plasma**  
134 **membrane is symmetric or asymmetric (16). In one widely cited and accepted study,**  
135 **it is proposed to be asymmetric (13),** with Ac<sub>2</sub>PIM<sub>2</sub> being the dominant species in the  
136 cytoplasmic leaflet accompanied by AcPIM<sub>2</sub>, while the periplasmic leaflet is more  
137 varied, containing AcPIM<sub>2</sub>, AcPIM<sub>6</sub>, Ac<sub>2</sub>PIM<sub>6</sub>, CL, PI, PE and TMM (6, 13, 17, 18).  
138 PIM<sub>6</sub> lipids can be further modified to LM and LAM that make up the bulk of the  
139 periplasmic space (19). Additionally, lipids have been shown to modulate membrane  
140 protein function (20, 21). However, due to the complexity of the mycobacterial cell  
141 envelope, the dynamics and properties of the plasma membrane is extremely difficult  
142 to probe experimentally.

143 Over the last decade, molecular dynamics (MD) simulations have emerged as  
144 a powerful strategy for studying structural and functional aspects of biomembranes  
145 (22, 23). However, at the time of writing, there are no complete models of the  
146 mycobacterial plasma membrane that capture a **possible** asymmetry and the diverse  
147 range of lipids (24). This limits our ability to understand *Mtb* plasma membrane biology,  
148 model drug-lipid interactions - important for anti-TB drug discovery efforts - and  
149 simulate mycobacterial membrane proteins in a native environment. Therefore, it is  
150 essential to develop models of the major phospholipids of the mycobacterial plasma  
151 membrane for application in MD simulations.

152 Herein, multiscale simulations were used to analyze the structure-function  
153 relationship of the four main PIM lipids (AcPIM<sub>2</sub>, Ac<sub>2</sub>PIM<sub>2</sub>, AcPIM<sub>6</sub> and Ac<sub>2</sub>PIM<sub>6</sub>) found  
154 in the mycobacterial membrane. An asymmetric bilayer containing these lipids was  
155 assembled and simulated, showing the stability of this composition. To highlight the  
156 robustness of our approach, additional simulations representing (in total) two different  
157 asymmetric growth stages as well as symmetric membrane configurations were  
158 performed. Systematic analysis of the distribution of *Mtb* protein residues in contact

159 with lipids reveals further indications that this membrane could possibly be  
160 asymmetric. We have also modelled how antibiotics, used to treat TB infections,  
161 diffuse through the membrane and interact with membrane proteins and demonstrated  
162 that our models agree with experimental results (25). Overall, we have developed  
163 robust possible representations of the mycobacterial plasma membrane that will  
164 enable studies of membrane dynamics, lipid interactions with integral membrane  
165 proteins, and diffusion of antibiotics across this barrier.

166

167

## 168 **Methods**

169

### 170 *Building the coarse-grained lipid parameters*

171 The CG models of the lipids were parametrized for the newly released MARTINI 3  
172 force field (26) and generated using the protocol described for small molecules (27)  
173 on the MARTINI website ([http://cgmartini.nl/index.php/martini-3-](http://cgmartini.nl/index.php/martini-3-tutorials/parameterizing-a-new-small-molecule)  
174 [tutorials/parameterizing-a-new-small-molecule](http://cgmartini.nl/index.php/martini-3-tutorials/parameterizing-a-new-small-molecule)). The bead types and mapping to the  
175 PIM molecules were performed manually, comparing with the recently published CG  
176 model of PI (28). Atoms were grouped according to functional groups, in sets of 3-5  
177 non-hydrogen atoms. The CG mapping of Ac<sub>x</sub>PIM<sub>x</sub> is shown in **Figures 1B,C**. The  
178 parameter files that describe the bonds, constraints, and angles were assembled  
179 based on the previously described data (26, 28, 29) as an initial estimate.

180 Simulations of each lipid were set up using a modified version of *insane.py*  
181 python script (30), embedding one copy of a PIM lipid in a 10 x 10 nm<sup>2</sup>  
182 phosphatidylcholine (PC) bilayer. The system was solvated with MARTINI water (26)  
183 and neutralized with 150 mM NaCl, followed by minimization using the steepest  
184 descents algorithm. The system was then simulated for 3 μs using a timestep of 20 fs  
185 at 310 K. The lipids, solvent and ions were temperature coupled separately. The  
186 velocity rescale (31) and Parrinello-Rahman (32) coupling methods were used with  
187 the time constants  $\tau_T = 1.0$  ps and  $\tau_p = 12.0$  ps for temperature and pressure,  
188 respectively. Simulations were run using GROMACS version 2021.3 (33). The  
189 reaction-field algorithm (34) was used for electrostatics interactions with a cut-off of  
190 1.1 nm. A single cut-off of 1.1 nm was used for the van der Waals interaction. Five  
191 repeats were performed for each lipid (**SI Figure 2**).

192

193 *Generating atomistic data*

194 Parameters for the atomistic (AT)  $Ac_xPIM_x$  lipids were generated using the CHARMM  
195 force field (35). The CHARMM-GUI (36) server was used to set up the lipid systems  
196 for GROMACS with the CHARMM36m force field (37, 38). One PIM lipid was  
197 embedded in an  $8 \times 8 \text{ nm}^2$  PC bilayer. The system was solvated with 150 mM NaCl  
198 and minimized and equilibrated as per the CHARMM-GUI Membrane Builder workflow  
199 (39). The system was further minimized using the steepest descents. Simulations  
200 were run for 2  $\mu\text{s}$  using a timestep of 2 fs at 310 K. The lipids, solvent and ions were  
201 temperature coupled separately. The velocity rescale (31) and C-rescale coupling  
202 methods were used with the time constants  $\tau_T = 0.1 \text{ ps}$  and  $\tau_p = 1.0 \text{ ps}$  for temperature  
203 and pressure, respectively. Simulations were run using GROMACS version 2021.3  
204 (33). The particle mesh Ewald (PME) (40) method was used for electrostatic  
205 interactions with a cut-off of 1.2 nm. A single cut-off of 1.2 nm was used for the van  
206 der Waals interaction. Three repeats were performed for each lipid (**SI Figure 2**).

207

208 *Refining coarse-grained parameters*

209 The AT and CG representations of the four main PIM lipids are shown in **Figure 1C**.  
210 The distributions of the distances and angles were measured using the *gmx* tools  
211 (*distance*, *gangle* and *analyze*). For the AT simulations, the atoms were grouped  
212 according to their mapping and its center of geometry was used for calculations. The  
213 values for each bond/constraint and angle were iteratively refined based on the  
214 comparison of probability distribution, and the results are summarized in **SI Figures**  
215 **3-8**. When there was agreement between the AT and CG data, the solvent accessible  
216 surface area was measured using the *gmx sasa* tool to verify that the models behaved  
217 the same (**SI Figure 8C**). Diffusion, shape of the lipids, clustering of ions, aggregation  
218 and interaction with other lipids were also measured on a single lipid level (**SI Methods**  
219 and **SI Figures 9-19**). As typical for MARTINI (41), dihedral terms are not defined in  
220 the parameters.

221

222 *Measuring area per lipid*

223 Before setting up the complete bilayer system, the area per lipid was measured. The  
224 simulations were assembled as described above for CG, using a homogenous  
225  $Ac_xPIM_x$  membrane (**SI Figure 2**). The area of XY-dimension was measured using  
226 *gmx energy* and then dividing the area by the number of lipids in one leaflet over the



227 course of the trajectory, and the final values were extracted using *gmx analyze*, as per  
228 the protocol described on the MARTINI website ([http://cgmartini.nl/index.php/tutorials-](http://cgmartini.nl/index.php/tutorials-general-introduction-gmx5/bilayers-gmx5#Area-per-lipid)  
229 [general-introduction-gmx5/bilayers-gmx5#Area-per-lipid](http://cgmartini.nl/index.php/tutorials-general-introduction-gmx5/bilayers-gmx5#Area-per-lipid)).

230

### 231 *Bilayer composition and set-up*

232 The ratio of lipids in each bilayer was obtained by using their molecular weight and the  
233 previously reported dry masses (13) of the individual lipids, and the exact calculations  
234 can be seen in **SI Figure 20**. Since specific apolar lipids were not named, they were  
235 not included in this study. TMM was not included as there is no available refined AT  
236 model, the behavior of the mycolic acid is predicted to be complicated (42), and there  
237 is a relatively small proportion of TMM predicted to be present in the plasma  
238 membrane. The final composition of the plasma membrane is shown in **Figure 1A**.

239 The PI and PE lipids in mycobacteria are slightly different in structure to the  
240 corresponding *E. coli* lipids described in the MARTINI force field (26, 28): a methyl  
241 group replaces the alkene found in one of the acyl chains (**SI Figure 1**). Before  
242 assembling the membrane, the parameters for these lipids were modified by adapting  
243 the refined Ac<sub>2</sub>PIM<sub>2</sub> acyl tail parameters and changing the existing tail. The CL  
244 parameters were transferred over from the MARTINI 3 beta force field (21).

245 Simulations of the bilayer were set up using a modified version of *insane.py*  
246 python script (30) using the composition shown in **Figure 1A**, where the area per lipid  
247 for the periplasmic membrane was set to 0.92 nm<sup>2</sup> and the cytoplasmic leaflet set to  
248 1.13 nm<sup>2</sup>. The systems were then treated the same as described for the initial CG  
249 systems with added equilibration steps as per the Membrane Builder workflow (39)  
250 before the production simulation. There were two types of system assembled **to**  
251 **represent the asymmetric membrane previously mentioned (13)**. The first one had an  
252 initial simulation box size of 20 x 20 x 15 nm<sup>3</sup> and one repeat was performed for 10 μs  
253 at 290 K, 300 K, 310 K, 320 K and 350 K (**Figure 2A**). The second one had an initial  
254 box size of 50 x 50 x 15 nm<sup>3</sup> and a single repeat was performed for 10 μs at 310 K  
255 (**Figure 2C** and **SI Figure 2**). The number of lipids in each system is summarized in  
256 **SI Figure 21**.

257 To test how the membrane properties change with differing compositions, the  
258 same assembly procedure was followed to set up a symmetric membrane and an  
259 'PIM-enriched' membrane (**SI Figure 22**), with one repeat for each in a simulation box  
260 of 20 x 20 x 15 nm<sup>3</sup>, and another in a box of 50 x 50 x 15 nm<sup>3</sup>, both at 310 K (**SI Figure**

261 2). Another membrane to capture an experimentally extracted membrane was  
262 simulated for 10  $\mu\text{s}$  in a 20 x 20 x 20 nm<sup>3</sup> simulation box at 310 K. The number of lipids  
263 in each system is summarized in **SI Figure 21** and their compositions in **SI Figure 22**

264

### 265 *Behavior of the membrane*

266 To calculate the bending rigidities, the strategy proposed by Fowler *et al.* (43) to  
267 extract the bending modulus from CG simulations was followed. The membrane  
268 midplane position in Monge representation was determined by extracting the  
269 coordinates of all CG beads at the extremities of lipid fatty acid chains. Using a built-  
270 in function of the Mathematica software package, the positions were interpolated to  
271 get a smooth function before Fourier-transforming with a fast Fourier transform  
272 algorithm. From the so-obtained Fourier modes, the spectral density (or power  
273 spectrum) was estimated for a tensionless membrane:

$$274 \quad S(q) = L^2 k_B T \left( 1/(\kappa q^4) + 1/(\sigma_p r q^2) \right)$$

275 where  $L^2$  is the projected area in the  $(x, y)$  plane,  $k_B T$  is the thermal energy and  
276  $\sigma_p r \sim 0.1 \text{ J/m}^2$  is the tension associated with lipid protrusions at the nanometer scale.  
277  $S(q)q^4$  was plotted as a function of  $q$  and fit it with a second order polynomial  $P(q) =$   
278  $a + bq^2$ , from which estimates of  $\kappa$  (and  $\sigma_p r$  if needed) were obtained (**SI Figure 23**).

279 The error bars are standard deviations provided by the fitting function in Mathematica.

280 The density of each constituent was measured using *gmx density* (**Figure 2B**).  
281 Diffusion, bilayer thickness and number of neighbors was measured using LiPyphilic  
282 (44) (**Figures 2D,E, SI Methods** and **SI Figures 24-27**). The xy-positions of single  
283 lipids were tracked with PLUMED (45) (**Figure 2E**). Area per lipid for the membrane  
284 was calculated using FATSLIM (46) (**Figure 2F**). Plots were created using Matplotlib  
285 (47).

286

### 287 *Analysis of the residue distribution in membrane proteins*

288 All predicted protein structures from *Mtb* (taxonomy id:83332) and *E. coli* (taxonomy  
289 id:83333) labelled as transmembrane on UniProt (48) were downloaded from the  
290 AlphaFold database (49), totaling 729 for *Mtb* and 1,229 for *E. coli*. Alphafold was used  
291 to obtain a workable dataset of structures, expanding upon the number of  
292 experimentally determined *Mtb* and *E. coli* membrane protein structures available from  
293 the PDB. Each of 1,958 membrane protein structures was orientated in a membrane

294 using memembed (50) with the *-n in* flag, then converted to CG using martinize2 (51)  
295 and inserted into either the asymmetrical mycobacterial (see **Figure 1A**) or *E. coli*  
296 membrane (75% PE, 15% PG, 10% CL) using a modified version of the *insane.py*  
297 python script (30). Each system was simulated for 10 ns. The residues within 8 Å of  
298 the lipids were selected and the density over the z-coordinate plotted (**Figure 3, SI**  
299 **Figure 28**).

300

### 301 *Antibiotic simulations*

302 Bedaquiline (BDQ) and isoniazid (ISZ) were mapped to CG using PyCGTOOL (52)  
303 following 200 ns AT simulations with parameters from CHARMM-GUI (53) (**Figure**  
304 **4A**). The pK<sub>a</sub> of the amine in BDQ is 8.91 (54), suggesting it will be protonated at  
305 physiological pH. This was considered when assigning the MARTINI 3 bead type  
306 (**Figure 4A**). To validate the use of the protonated state, the same simulations with a  
307 neutral BDQ molecule were performed and analyzed (**SI Figures 29A-C**). This was  
308 done by replacing the Q1 particle with a SC3 bead type (**Figure 4A**). In addition, the  
309 LogP for these antibiotics were calculated by perturbing the antibiotic in a box  
310 containing 878 MARTINI waters or 363 octanol and 32 waters. The Lennard-Jones  
311 parameters for each molecule were decoupled over 11 evenly spaced  $\lambda$  windows, for  
312 50 ns per window. Simulations were run with 20 fs time steps in the NPT ensemble  
313 with the V-rescale thermostat at 323 K and an isotropic Parrinello-Rahman pressure  
314 coupling. Free energies were then computed using *gmx bar* and converted to  
315 water/octanol partitioning constants. The values were then compared to data from the  
316 ALOGPS online server (55). Alongside this, *gmx sasa* was used to calculate the  
317 solvent accessible surface area for the antibiotics in both CG and AT. The calculations  
318 were performed with 4800 dots per sphere and a probe size of 0.4 nm. Modified van  
319 der Waals radii for CG beads of 0.264, 0.230, and 0.191 nm for R, S and T beads  
320 were used respectively. For the Connolly surface generation, the calculations used  
321 240 dots and a probe of 0.4 nm (**SI Figure 30**).

322 BDQ was first simulated with the mycobacterial membrane alone to confirm  
323 association with the membrane (**SI Figures 2,31**). The *Mtb* a- and c-subunits of F-  
324 ATPase, BDQ's target in the mycobacterial membrane, was modelled using  
325 SwissModel (56) based on a structure from *Mycobacterium smegmatis* (25) (PDB:  
326 7JGC, **Figure 4C** and **SI Figures 32A,B**). The sequence identity between *Mtb* and *M.*  
327 *smegmatis* for the F-ATPase was calculated using Clustal Omega (57) at 80% and

328 72% for c- and a-subunits, respectively. The system with the protein in the **asymmetric**  
329 **mycobacterial membrane (see Figure 1A)** was assembled using martinize2 (51),  
330 memembed (50) and the modified *insane.py* python script (30), with eight molecules  
331 of BDQ placed either in the periplasmic or cytoplasmic leaflet with five repeats in each  
332 membrane (**SI Figure 2**). Simulations were run for 10  $\mu$ s using the same setting as  
333 described above. The xyz-positions of BDQ, the lipids and the backbone beads were  
334 tracked over the course of the simulations with PLUMED (45) and plotted with  
335 Matplotlib (47), and the results are shown in **Figure 4D** and **SI Figures 32C,D, 33**.  
336 The density of each constituent was measured using *gmx density* and plotted using  
337 Matplotlib (47) and the results are shown in **Figure 4E** (with representative positions  
338 shown in **Figure 4F**). The interaction of BDQ with the protein was calculated using  
339 PyLipID (58) (**Figure 4G** and **SI Figures 34,35**). The same simulation set up was  
340 performed with a model *E. coli* membrane (75% PE, 15% PG, 10% CL) and with the  
341 symmetric mycobacterial membrane (**SI Figure 22A**). The z-position of BDQ is shown  
342 in **SI Figure 32** and **SI Figures 36,37**.

343

#### 344 *PMF calculations*

345 The potential of mean force (PMF) calculations for the F-ATPase-BDQ interaction  
346 were performed (59). First, a representative pose of BDQ bound to the protein was  
347 produced using PyLipID from equilibrium simulations and built into a 12 x 20 x 11 nm<sup>3</sup>  
348 **asymmetric mycobacterial membrane (see Figure 1A)** membrane and minimized and  
349 equilibrated, as described above. Light (50 kJ/mol/nm<sup>2</sup>) xy positional restraints were  
350 added to Ala 66 on three c-subunits to prevent the protein from rotating in the  
351 membrane. Following 50 ns of equilibration, the BDQ was steered away from the  
352 protein along the y axis at a rate of 1 nm/ns with a 1,000 kJ/mol/nm<sup>2</sup> restraint potential.  
353 Frames were extracted at 0.1 nm spacing along this coordinate to seed a total of 58 x  
354 1.5  $\mu$ s production simulations with a static 1,000 kJ/mol/nm<sup>2</sup> umbrella potential  
355 imposed to keep the system in the same position along the reaction coordinate. The  
356 PMF mdp input files can be downloaded at <https://github.com/chelsea-brown/PIM-lipids/tree/main/PMF-files>. The PMF profiles were then constructed using the weighted  
357 histogram analysis method in GROMACS (*gmx wham* (60, 61)), and employing 200  
358 rounds of Bayesian bootstrapping to report statistical accuracy (**Figure 4H**).

360 For the membrane crossing PMFs, BDQ or ISZ was placed free in the solvent  
361 phase, 7 nm away from the membrane periphery in either an **asymmetric**

362 **mycobacterial membrane (see Figure 1A)** or *E. coli* membrane. The drug was then  
363 steered towards and through the membrane and into the solvent phase on the other  
364 side. Windows were extracted, simulated (1  $\mu$ s for ISZ per window and 2  $\mu$ s per  
365 window for BDQ) and analyzed as described above (**Figure 4B** and **SI Figure 29D** for  
366 BDQ neutral). The -cycl option was imposed when running *gmx wham*.

367

## 368 **Results**

369

### 370 *PIM properties*

371 As an initial step towards developing an *in-silico* model of the mycobacterial plasma  
372 membrane, we first examined lipid properties in our CG and AT models. As shown in  
373 **SI Figures 3-8**, the probability distributions of bonds and angles from the CG and AT  
374 simulations align well, which illustrates that the behavior of the acyl chains is similar  
375 to other phospholipids (30). The Ac<sub>x</sub>PIM<sub>x</sub> aggregation in the AT and CG simulations is  
376 comparable and shows no permanent clustering. When lipids did come into contact,  
377 all areas of the molecule appear to play an equal role in the interactions (**SI Figures**  
378 **15,17**). The interactions were not dominated by the sugars, as was seen with the  
379 previous iteration of the MARTINI 2 force field (62), and the phospholipids present in  
380 the mycobacterial membrane did not have strong interactions with the PIM lipids (**SI**  
381 **Figure 18,19**). The PIM lipids show a higher affinity for ions than PC in CG simulations,  
382 but the effect is less apparent in AT simulations (**SI Figure 14**). While the ion  
383 concentrations were the same, the number of ions in the simulation box were different  
384 (an order of magnitude higher for CG), which could explain these results. Overall, CG  
385 simulations of these lipids behave similarly to AT models (interactions with ions as a  
386 minor exception), therefore opening the door to significantly longer simulations by  
387 decreasing the degrees of freedom in the system.

388 The area per lipid in CG for each species in a PC bilayer was found to be 0.93  
389 nm<sup>2</sup> (AcPIM<sub>2</sub>), 1.15 nm<sup>2</sup> (Ac<sub>2</sub>PIM<sub>2</sub>), 1.01 nm<sup>2</sup> (AcPIM<sub>6</sub>), 1.14 nm<sup>2</sup> (Ac<sub>2</sub>PIM<sub>6</sub>), 0.6 nm<sup>2</sup>  
390 (PI), 0.55 nm<sup>2</sup> (PE) and 1.25 nm<sup>2</sup> (CL). The diffusion coefficients for each PIM species  
391 in a PC bilayer at 310 K are as follows: 6.7 x 10<sup>-7</sup> cm<sup>2</sup>/s (AcPIM<sub>2</sub>), 1.1 x 10<sup>-7</sup> cm<sup>2</sup>/s  
392 (Ac<sub>2</sub>PIM<sub>2</sub>), 7.6 x 10<sup>-7</sup> cm<sup>2</sup>/s (AcPIM<sub>6</sub>), 6.5 x 10<sup>-7</sup> cm<sup>2</sup>/s (Ac<sub>2</sub>PIM<sub>6</sub>) (**SI Figure 9**). The  
393 difference between AcPIM<sub>x</sub> and Ac<sub>2</sub>PIM<sub>x</sub> shows the effect of the extra acyl tail in terms  
394 of how freely these lipids diffuse through the membrane.

395 The lipid shapes are approximately the same from AT to CG (**SI Figures 10-**  
396 **13**), which agrees with the comparison of the surface areas (**SI Figure 8C**) and the  
397 sugar-phosphate z-distances in Ac<sub>x</sub>PIM<sub>6</sub> (**SI Figures 5C,7C**). The additional mannose  
398 moieties project upwards away from the membrane in both sets of simulations.  
399 Interestingly, the lipid tail region is measured to occupy approximately the same  
400 amount of space with three or four acyl chains. This is likely due to the placement of  
401 the fourth tail, projecting downwards from the inositol sugar (as highlighted in red in  
402 **Figure 1B**) and hence inhabiting space close to the other acyl chains.

403 Taken together, the lipid properties in our CG model broadly replicate those  
404 seen with AT resolution. This provided the confidence to assemble these lipids into a  
405 complex bilayer.

406

#### 407 *Mycobacterial membrane biophysical properties*

408 Traditional MD simulations of bacterial membranes use symmetric bilayer  
409 representation. However, a study has shown that the mycobacterial plasma  
410 membrane could be an asymmetric bilayer, and we used the published composition  
411 of the mycobacterial plasma membrane (13) (**Figure 1A**) (excluding apolar lipids and  
412 TMM) to assemble an asymmetric bilayer (**Figures 2A,C**). This bilayer was found to  
413 be stable during 10 μs simulation (**SI Movie 1**), and in good agreement with the  
414 literature (8, 13). The thickness of the plasma membrane in our simulations was at 5.3  
415 ± 0.1 nm (**Figure 2B**), which is slightly narrower than values obtained from imaging  
416 studies (6.3 nm for *Mycobacterium bovis* and 7 nm for *Mycobacterium smegmatis*)  
417 (63-65). However, we did observe thicknesses of up to 7 nm in the density plot (**Figure**  
418 **2B**). *In vitro* culture conditions or growth stages of the bacteria (65) impact the  
419 thickness on the membrane and could explain any minor differences with our model.

420 To test the phase behavior of this membrane, we performed simulations at  
421 various temperatures ranging from 290 K to 350 K. For the whole range of  
422 temperatures, lipids were in the liquid phase and allowed to diffuse freely (**Figure 2E**  
423 and **SI Figure 24**). The calculated diffusion coefficients for each species in the  
424 periplasmic leaflet at 310 K were as follows: 9.9 × 10<sup>-8</sup> cm<sup>2</sup>/s (AcPIM<sub>2</sub>), 6.9 × 10<sup>-8</sup> cm<sup>2</sup>/s  
425 (AcPIM<sub>6</sub>), 1 × 10<sup>-7</sup> cm<sup>2</sup>/s (Ac<sub>2</sub>PIM<sub>6</sub>), 1.3 × 10<sup>-7</sup> cm<sup>2</sup>/s (PI), 1.5 × 10<sup>-7</sup> cm<sup>2</sup>/s (PE) and 1.2  
426 × 10<sup>-7</sup> cm<sup>2</sup>/s (CL). In the cytoplasmic leaflet, the values were 6.1 × 10<sup>-8</sup> cm<sup>2</sup>/s (AcPIM<sub>2</sub>)  
427 and 8.1 × 10<sup>-8</sup> cm<sup>2</sup>/s (Ac<sub>2</sub>PIM<sub>2</sub>). Compared to isolated PIMs in a PC membrane, the  
428 diffusion in this plasma membrane was roughly one order of magnitude slower.

429 AcPIM<sub>2</sub>, which is the only lipid in both leaflets, diffused ~40% slower in the cytoplasmic  
430 membrane compared with the periplasmic leaflet. Using a previously reported model  
431 of mammalian plasma membrane (22), the diffusion coefficients of PE and PI were  
432 calculated to be  $3.3 \times 10^{-7} \text{ cm}^2/\text{s}$  and  $2.8 \times 10^{-7} \text{ cm}^2/\text{s}$ , showing that the diffusion in the  
433 mammalian membrane is equivalent to that in the mycobacterial plasma membrane.  
434 The membrane stiffness of our mycobacterial membrane was significantly lower at  
435  $\kappa = 8.2 \text{ k}_B\text{T}$  compared to  $13.9 \text{ k}_B\text{T}$  and  $19.1 \text{ k}_B\text{T}$  for the mammalian and PC membrane  
436 models, respectively (**SI Figure 23**), highlighting a unique dynamic behavior for the  
437 mycobacterial plasma membrane.

438 Lipid clustering was moderate and membrane composition remained  
439 heterogeneous over the course of each  $10 \mu\text{s}$  simulation (**Figure 2C**). This can also be  
440 seen in **Figure 2D** where the number of surrounding lipids of the same type for each  
441 species in the periplasmic membrane was roughly equivalent to that of any other lipid  
442 species. The distribution of the area per lipid in the membrane also suggests high  
443 heterogeneity (**Figure 2F**). The average area per lipid in the membrane over the  
444 course of the simulation was  $0.89 \text{ nm}^2$  and  $1.18 \text{ nm}^2$  for the periplasmic and  
445 cytoplasmic leaflets, respectively. Thus, the cytoplasmic leaflet appears to be a little  
446 denser than the periplasmic leaflet. This can be related to the packing of the four acyl  
447 chains of Ac<sub>2</sub>PIM<sub>2</sub> lipids present in high concentration in this leaflet (66). A movie for  
448 the change in area per lipid for each leaflet over the course of the simulation can be  
449 found in **SI Movies 2,3**.

450 As was seen for the individual lipids in CG the overall bilayer attracted ions;  
451 both Cl<sup>-</sup> and Na<sup>+</sup> concentration was much higher close to the bilayer, especially around  
452 the sugar head groups compared to bulk solution (**Figure 2B**). It has been shown that  
453 lipid-ion interactions can affect the biophysical properties of the membrane, such as  
454 fluidity and stiffness, as well as the structure, which could modify the interaction with  
455 proteins (67).

456 The mycobacterial plasma membrane has been reported to change at different  
457 growth stages (7, 68), but the study that originally proposed the composition was  
458 based solely on late-exponential-phase cells. To explore a wider range of possible  
459 membrane compositions, we designed an 'PIM-enriched' bilayer, where the amount  
460 of PIM lipids in the periplasmic leaflet was increased to reflect cells in rapid growth (7)  
461 (see compositions in **SI Figure 22**). In this case, the overall biophysical properties of  
462 that leaflet were very similar to those seen in **Figure 2**, but interestingly a change in



463 the diffusion and density of the cytoplasmic leaflet was observed (**SI Figures 26,27**).  
464 Increasing the proportion of lipids in the periplasmic leaflet that have 3 or 4 acyl chains  
465 could mean that the lipid tails make more inter-leaflet interactions and hence slow  
466 down diffusion and make the leaflet denser. This decrease in fluidity in the membrane  
467 could impact antibiotic diffusion through the membrane (13, 69) which would make the  
468 bacteria less susceptible to treatment at a time when it is most vulnerable.

469 We have also tested alternative plasma membrane compositions with a  
470 symmetrical configuration. First, we performed a model of a membrane recapitulating  
471 the composition being experimentally derived using a combination of mass  
472 spectrometry and NMR (see composition in **SI Figures 22,38**). This symmetrical  
473 configuration is stable, and the dynamics of PIM lipids in CG-MD simulations agreed  
474 with solid state NMR results (see **SI Figures 38,39**). This data shows that the acyl  
475 chains extremities are highly mobile, while the core of the acyl chains displayed a more  
476 rigid structure. Interestingly, the sugar moieties adopted an intermediate dynamic  
477 regime, as seen from experimental NMR results (**SI Figure 38E**) and MD simulations  
478 (**SI Figure 39B**). We then designed a model of symmetrical membrane system with a  
479 lipid composition that mimics *Mtb* membranes (see composition in **SI Figure 22A**).  
480 This membrane showed similar interactions of lipids compared to the asymmetric  
481 composition and also similar rates of diffusion (**SI Figures 25,27**). Clustering of ions  
482 around the sugar headgroups was still observed.

483 Taken together our observations suggest that PIM lipids play a critical role in  
484 the dynamic and structuration of mycobacterial plasma membrane. **Both the**  
485 **asymmetric and symmetric configurations of the membrane were equally stable and**  
486 **our analyses show that both share similar dynamic properties. This work demonstrates**  
487 **the plausible arrangements of the plasma membrane and provides a mechanism to**  
488 **easily study new membrane compositions based on future experimental results.**

489

#### 490 *Asymmetrical distribution of residues at the surface of Mtb membrane proteins*

491 The lipids of the plasma membrane do not exist in isolation, but rather in cooperation  
492 with membrane proteins. These proteins could provide insights into how this  
493 membrane exists natively (70). To explore this, we used the accurate, fast and reliable  
494 workflows of AlphaFold (49) and memembed (50), to insert all transmembrane  
495 proteins from *Mtb* and *E. coli* into their native-like membranes (**Figure 3A,B**). We then  
496 assessed the distribution of residues in proximity to the lipid bilayer (**Figure 3C**).



497 For *E. coli*, the distribution is as expected and similar to results previously  
498 shown (21). The asymmetry of Arg and Lys reflect the 'positive inside rule' (71-73)  
499 present in bacteria which aids in the correct insertion of the transmembrane helices.  
500 The symmetric nature of the lipid bilayer is otherwise reflected in the distribution of the  
501 residues (**Figure 3C**, **SI Figure 28**). The *Mtb* distribution of Arg also shows a strong  
502 'positive inside rule'. This is at a higher intensity than in *E. coli*, likely due to the low  
503 levels of Lys observed (**Figure 3C**). Furthermore, the decrease in the bulky Phe and  
504 Tyr residues (**Figure 3C**) in the cytoplasmic leaflet compared to the periplasmic leaflet  
505 agrees with the increased density seen in an asymmetric membrane (**Figure 2B** and  
506 **SI Figure 26B**).

507 These results add evidence to an asymmetric model previously proposed (13).  
508 In addition to validating the model proposed in this work, it could aid understanding of  
509 how mycobacterial membrane proteins differ from those found in other organisms and  
510 hence aid targeted therapies.

511

#### 512 *Asymmetric interaction of the membrane with antibiotics*

513 We were interested in testing how the organization of this membrane affects the  
514 behavior of other molecules, such as antibiotics. We tested two widely used anti-TB  
515 antibiotics: Isoniazid (ISZ) and Bedaquiline (BDQ) (**Figure 4A**). To validate the  
516 behavior of these small molecules as well as the bond lengths/angles being account  
517 for through PyCGTOOL (52) (**SI Figure 30**), the LogP and solvent accessible surface  
518 area were calculated for each and compared to predicted values and atomistic values,  
519 respectively. The values for LogP for neutral BDQ (5.92 for CG, 6.37 predicted) and  
520 ISZ (-1.10 for CG, -0.71 predicted) agree very well, as do the solvent accessible  
521 surface area values (BDQ values  $13.01 \pm 0.49$  nm<sup>2</sup> for CG and  $13.69 \pm 1.11$  for AT;  
522 ISZ values  $7.48 \pm 0.14$  nm<sup>2</sup> for CG and  $7.35 \pm 0.04$  for AT).

523 ISZ is a first line anti-TB treatment that targets InhA, a cytosolic enzyme that is  
524 essential for mycolic acid synthesis (74). BDQ on the other hand is a last line antibiotic  
525 that targets the membrane protein complex of the ATP synthase (75, 76). The PMF  
526 results for ISZ and BDQ show that the mycobacterial membrane behaves as expected  
527 regarding the passage of a small molecule through a lipid rich membrane, showing  
528 favorable interactions with the largely hydrophobic BDQ and unfavourable interactions  
529 with hydrophilic ISZ (**Figure 4B**). The positive charge present on BDQ could account  
530 for the sharp free energy barrier at the membrane midplane. To assess the effect of

531 the charge on the passage of BDQ since the protonation state is unknown, we  
532 modeled a neutral BDQ where the charged Q1 bead (see **Figure 4A**) was replaced  
533 by SC3. The PMF results with the neutral BDQ show a reduction in the energy barrier  
534 at this point (**SI Figure 29D**). We note that the passage of these drugs through an *E.*  
535 *coli* inner membrane is symmetric from the mid-plane of the membrane as expected.  
536 The interactions of BDQ with the periplasmic leaflet of the mycobacterial membrane  
537 were ~6 kJ/mol stronger than for the simple membrane and the mycobacterial  
538 cytoplasmic leaflet. This is possibly due to the presence of tetraacylated PIMs in the  
539 mycobacterial periplasmic leaflet. Roughly the same difference between the  
540 mycobacterial and simple membranes was observed for ISZ at the mid-membrane  
541 region, showing less favorable passage through the membrane. These results suggest  
542 that ISZ, a first-line TB drug, is unlikely to freely diffuse through the membrane, which  
543 is in contrast with the previously proposed uptake mechanism based on passive  
544 diffusion (77-79). Small differences were seen for ISZ interactions at the interfaces of  
545 the mycobacterial and simple membrane periplasmic membrane. This could be due to  
546 the presence of certain PIM lipids in this leaflet. In our simulations, when the BDQ  
547 starting position was in the bulk solvent, the drug quickly associated with the  
548 membrane, as shown in **SI Figure 31**, and displayed no strong preference for either  
549 leaflet in these simulations.

550 BDQ has been shown to target the mycobacterial ATP synthase (Rv1304-  
551 Rv1311), a membrane protein complex. A cryo-EM structure from *M. smegmatis*  
552 (PDB: 7JGC) shows multiple binding sites for BDQ at the interface of the c-subunits  
553 and the interface between the a- and c- subunits (25), where a highly negatively  
554 charged area is located (**SI Figure 32A,B**). Using the available cryo-EM data, we  
555 performed 10 simulations of 10  $\mu$ s each to examine how *Mtb* ATP synthase complex  
556 behaves in our **asymmetric** mycobacterial plasma membrane model. ATP synthase  
557 was stable in the membrane and that there were no significant perturbations of the  
558 bilayer by the protein. The lipids of the mycobacterial membrane did not show any  
559 strong interactions with the protein (**Figure 4D** and **SI Figure 33**), apart from CL that  
560 localizes in the a-subunit and around the c-ring (**Figure 4D**) in positions similar to  
561 those observed in a previous study (80). The exact values for CL occupancy of each  
562 residue are shown in **SI Figure 35A**. Minimal interactions between BDQ and the  
563 ATPase occurred when the drug started in the periplasmic leaflet; however, when BDQ  
564 was introduced in the cytoplasmic leaflet, significant occupation of the binding sites on

565 ATPase were observed (**Figures 4D-G** and **SI Figures 32C,D**). The interactions were  
566 reduced with the neutral BDQ model (**SI Figures 29A-C**). Of note, no such leaflet  
567 differences were observed when we tested the *E. coli* symmetric membrane model (**SI**  
568 **Figures 36C,D; SI Figure 37**), but with a symmetric mycobacterial membrane (**SI**  
569 **Figure 32**). This suggests that the lipid composition plays a crucial role in the  
570 regulation of antibiotic interactions.

571 Furthermore, the interactions of the charged BDQ we observed matched well  
572 with what was previously seen in the cryo-EM structure (25), with an occupancy of  
573 ~30% of the simulation time on some subunits (**Figure 4G**). The occupancy value  
574 averaged over all subunits is shown in **SI Figure 35B**. The simulations were able to  
575 identify all three types of sites reported previously (25). Most interactions were seen  
576 through the leading site (46% of the time,  $K_{off} = 5.2 \mu s^{-1}$ ) followed by the lagging site  
577 (22% of the time,  $K_{off} = 7.6 \mu s^{-1}$ ) and finally further interactions around the rotor (36%  
578 of the time,  $K_{off} = 1.2 \mu s^{-1}$ , **SI Figure 34**). For the leading site, the PMF calculations  
579 confirm this as a binding site, giving a moderate energy well of approximately 7 kJ/mol  
580 (**Figure 4H**) and making it equivalent to a typical cholesterol-protein binding interaction  
581 (81). Tracking the z-position of the central bead from the antibiotic over the course of  
582 the unbiased simulations with the protein shows that the binding sites are occupied to  
583 some extent by each of the drug molecules and some are flipped to the outer leaflet  
584 from the plasma leaflet, as shown in **SI Figure 32C**.

585 These studies illustrate that our asymmetrical mycobacterial plasma  
586 membrane model can be combined with studies of antibiotics, as well as with studies  
587 of membrane proteins and their interactions with lipids and/or antibiotics. Taken  
588 together, our simulations suggest that BDQ must enter the target protein from the  
589 cytoplasmic side, which agrees with resistance mechanisms against BDQ that involve  
590 upregulation of MmpL5, a drug efflux pump (82, 83). Importantly, an *E. coli* membrane  
591 could not capture this feature, highlighting that the mycobacterial membrane model is  
592 a more accurate and functionally relevant representation of the *Mtb* plasma  
593 membrane.

594

## 595 **Discussion**

596 Here, we provide models for lipids constituting the mycobacterial plasma membrane  
597 focused on the PIM lipids, as they represent more than 50% of the total lipid content  
598 in *Mtb*. Thus, understanding how these lipids behave on an individual level and as a

599 constituent of a membrane could provide key insight into the intrinsic resistance of *Mtb*  
600 to antibiotics.

601 In this CG model, clustering of ions around these lipids was observed at both  
602 the single lipid and bilayer level, probing how this affects the biophysical properties of  
603 the bilayer and whether this could be exploited for treatment of TB is an interesting  
604 area for future research. The lipids did not cluster together excessively over the  
605 timescales studied and all diffused well through the membrane. This confirmed that  
606 the mycobacterial cell envelope is dynamic, which could potentially be an important  
607 insight into how this cell wall functions. A low membrane bending rigidity compared to  
608 a PC and eukaryotic plasma membrane is interesting and could suggest the  
609 importance of other cell envelope components in maintaining the shape of the cell.

610 The simulations confirmed that our asymmetric plasma membrane model is  
611 stable with a composition of over 50% PIM lipids. **However, considering that this**  
612 **arrangement has not been experimentally validated, a symmetric and 'enriched PIM'**  
613 **asymmetric membrane was also shown to share similar biophysical properties. The**  
614 **high proportion** of PIM lipids resulted in some unique properties, most notably lower  
615 membrane stiffness, which may have important implications for membrane  
616 microdomain formation, drug penetration, and integral membrane protein behavior. In  
617 this context, the integral membrane proteins from *Mtb* are of interest for the  
618 development of new antibiotics for TB (9), and we show evidence that our membrane  
619 model can be used to simulate proteins in a native lipid environment to determine any  
620 key lipid interactions, as illustrated by our study of antibiotic BDQ and its target,  
621 ATPase. In addition, an overall comparison of plasma membrane protein residues  
622 found in contact with the lipid bilayer revealed differences between *Mtb* and *E. coli*,  
623 supporting the asymmetric nature of the mycobacterial plasma membrane model. This  
624 potentially hints at topological differences between proteins in mycobacteria and those  
625 within other bacteria. If this is the case, currently unknown proteins which maintain the  
626 asymmetry might be present (such as those identified in animal cells (84)), and would  
627 constitute interesting drug targets to explore.

628 Potential limitations of our model stem from the reduced type of lipids we  
629 included in this initial development. Thus, future studies will focus on expanding the  
630 model to include apolar lipids (such as triglycerides (17)), TMM and LM/LAM.  
631 Moreover, future simulations with proteins and probing protein/lipid interactions with  
632 atomistic resolution could help further elucidate the role of these complex lipids.

633 In conclusion, our study is a starting point for building an entire mycobacterial  
634 cell envelope, as done for gram-negative bacteria (85). Other mycobacterial lipids  
635 have already been parameterized (86), and combining them with the model described  
636 here has the potential to significantly advance the field that has been lacking  
637 experimental strategies for plasma membrane investigations. Additionally, the  
638 mycobacterial cell envelope is known to change at different growth stages during its  
639 lifecycle (7, 68, 87, 88) and in response to different environments (69). With our model  
640 and set-up methods, as shown with the multiple compositions simulated, it will be  
641 possible to understand drug permeability or protein behavior at different stages of  
642 infection. Taken together, integrating our mycobacterial plasma membrane model into  
643 broader studies of this pathogen, its pathogen/host interactions, as well as into anti-  
644 TB drug discovery and development has a potential to reveal new functional insights  
645 and yield improved therapies.

646

647 Data availability: <https://github.com/pstansfeld/PIM-lipids>

648 Atomistic systems and CG-membrane set-up can be performed using respectively  
649 CHARMM-GUI bilayer builder ( <https://charmm-gui.org/input/membrane.bilayer> ) and  
650 CHARMM-GUI MARTINI bilayer Maker (   
651 <https://charmm-gui.org/?doc=input/martini.bilayer> )

652

### 653 **Author contributions**

654 C.M.B., R.A.C., W.I., P.J.S. and M.C. designed research; C.M.B., R.A.C., Y.G., Y.K.C.  
655 and E.L. performed computational research; C.M.B., R.A.C. and N.D. analyzed  
656 computational data; A.G., M.G., J.N. and A.L. performed experimental research and  
657 analysis; C.M.B., R.A.C., A.L., P.J.S. and M.C. wrote the paper; J.N., A.L., E.F., W.I.,  
658 P.J.S. and M.C. obtained funding.

659

### 660 **Acknowledgements**

661 C. M. B. is supported by an MRC studentship (MR/N014294/1). R. A. C. is funded by Wellcome  
662 (208361/Z/17/Z). Research in P. J. S.'s lab is funded by Wellcome (208361/Z/17/Z), the MRC  
663 (MR/S009213/1) and BBSRC (BB/P01948X/1, BB/R002517/1 and BB/S003339/1). M. C. is  
664 supported by the CNRS-MITI grant "Modélisation du vivant" 2020. W. I. is funded by NSF  
665 (MCB-2111728). E.F is a Sir Henry Dale Fellow jointly funded by the Wellcome Trust and  
666 Royal Society (104193/Z/14/Z and 104193/Z/14/B). M. G. would like to acknowledge the

667 European Union's Horizon 2020 research and innovation program under grant agreement  
668 H2020-PHC-08-2014-643381, TBVAC2020. This work was granted access to the HPC  
669 resources of CALMIP supercomputing center (under the allocation 2021-17036) and TGCC  
670 Joliot-Curie supercomputer (under the GENCI allocation A0110712941). This project made  
671 use of time on ARCHER2 and JADE2 granted via the UK High-End Computing Consortium  
672 for Biomolecular Simulation, HECBioSim (<http://hecbiosim.ac.uk>), supported by EPSRC  
673 (grant no. EP/R029407/1). This project also used Athena and Sulis at HPC Midlands+, which  
674 were funded by the EPSRC on grants EP/P020232/1 and EP/T022108/1. This work has  
675 benefited from the facilities and expertise of the Biophysical and Structural Chemistry platform  
676 (BPCS) at IECB, CNRS UAR3033, INSERM US001, and Bordeaux University. We thank the  
677 University of Warwick Scientific Computing Research Technology Platform for computational  
678 access. We acknowledge Life Science Editors for proofreading the manuscript. We thank C.  
679 Cooper for fruitful discussions and M. Costic for comments on the manuscript.  
680

681 **Abbreviations**

682	AT:	Atomistic
683	ATP:	Adenosine triphosphate
684	BDQ:	Bedaquiline
685	CG:	Coarse grained
686	CL:	Cardiolipin
687	ISZ:	Isoniazid
688	LAM:	Lipoarabinomannan
689	LM:	Lipomannan
690	MD:	Molecular dynamics
691	<i>Mtb</i> :	<i>Mycobacterium tuberculosis</i>
692	NMR:	Nuclear magnetic resonance
693	PC:	Phosphatidylcholine
694	PE:	Phosphatidylethanolamine
695	PG:	Phosphatidylglycerol
696	PI:	Phosphatidylinositol
697	PIMs:	Phosphatidyl- <i>myo</i> -inositol mannosides
698	PIPs:	Phosphatidylinositol phosphates
699	PME:	Particle mesh Ewald
700	PMF:	Potential of mean force
701	TB:	Tuberculosis
702	TMM:	Trehalose monomycolate
703	VdW:	van der Waal
704		

## 705 Figure Legends

706

707 **Figure 1:** The structure of the mycobacterial lipids. **(A)** Schematic of an asymmetrical model  
708 of the mycobacterial plasma membrane and composition as previously defined (13). **(B)**  
709 Schematic of the core of the PIM lipids found in mycobacteria with the groupings for coarse-  
710 grained (CG) beads. The inositol core is highlighted in red. The bead types for MARTINI 3 are  
711 shown. **(C)** Overlay of the AT (sticks) and CG (spheres) models for each lipid, with chemical  
712 characteristics shown to the right.

713 **Figure 2:** A mycobacterial membrane model. **(A)** Side view of the membrane with each lipid  
714 type depicted in a different color as shown in **Figure 1A**. **(B)** A density plot showing the density  
715 of water, sugar groups, phosphate groups, tail groups and ions over the simulation box. **(C)**  
716 Snapshots of the periplasmic and cytoplasmic leaflets whose compositions are: AcPIM<sub>2</sub> 22%,  
717 AcPIM<sub>6</sub> 11%, Ac<sub>2</sub>PIM<sub>6</sub> 10%, CL 24%, PE 20% and PI 13% (periplasmic leaflet) and AcPIM<sub>2</sub>  
718 10% and Ac<sub>2</sub>PIM<sub>2</sub> 90% (cytoplasmic leaflet). The system size is 50 x 50 x 15 nm. **(D)** Relative  
719 number of neighbors of each lipid type for the periplasmic membrane. **(E)** Mean squared  
720 displacement (MSD<sub>xy</sub>) (nm<sup>2</sup>) as a function of lagtime (ns) for each lipid type in the periplasmic  
721 and cytoplasmic leaflets. The inserts show the position of the phosphate group of each lipid  
722 type over the last 500 ns of the simulation. **(F)** Contour plots of the area per lipid (nm<sup>2</sup>) in each  
723 leaflet at the starting frame (upper) and final frame (lower) of the simulation. A darker color  
724 indicates a larger area per lipid.

725 **Figure 3:** The asymmetry of the mycobacterial membrane. **(A)** A simplified workflow for the  
726 lipid contacts analysis from all membrane proteins. **(B)** An example of a protein (*E. coli* protein  
727 MraY UniProt id: P0A6W3 and *Mtb* transporter MmpL3 UniProt id: P9WJV5) embedded in  
728 either an *E. coli* or mycobacterial membrane. The orange spheres represent phosphates. For  
729 *E. coli* membrane the cyan sticks show PG and the grey sticks PE. For mycobacterial  
730 membrane, the lipid sticks are shown in the colors illustrated in **Figure 1A**. Selected residues  
731 are colored according to the key in (C). **(C)** Graphs for *E. coli* and *Mtb* (top and bottom  
732 respectively) showing the relative abundance of selected residues within 8 Å of lipids. The  
733 gray lines show the position of the phosphates. The cytoplasmic region is shown by negative  
734 z values, the periplasmic region by positive values.  
735

736 **Figure 4:** The behavior of the antibiotics with mycobacterial membrane and proteins. **(A)**  
737 Chemical structures of BDQ and ISZ with the CG groupings overlaid and bead types shown.  
738 **(B)** PMFs of the two antibiotics being pulled through either a mycobacterial or simple  
739 membrane in the z-direction. BDQ is shown in blue and ISZ in red, with the mycobacterial  
740 membrane results having a solid line and simple membrane having a dashed line. The error  
741 is shown in grey. A schematic of the PMF is shown to the left. **(C)** Structure of *Mycobacterium*  
742 *smegmatis* ATP synthase (PDB: 7JG5) with the c-subunits shown in grey, the a-subunit shown  
743 in cyan, and the other components shown as a gold surface. **(D)** Density in the x and y  
744 dimensions of selected lipids and BDQ when starting in the cytoplasmic leaflet relative to the  
745 protein shown in grey. **(E)** Density of the phosphates (orange) and BDQ over the course of  
746 the simulations where the antibiotic started in either the periplasmic leaflet (green) or the  
747 cytoplasmic leaflet (blue). **(F)** Snapshot of a single simulation containing a *Mtb* ATPase model  
748 and 8 x BDQ models showing the main positions BDQ occupied. Phosphates are shown in  
749 orange, BDQ shown in blue, c-subunits are shown in grey, and the a-subunit is shown in cyan.  
750 The lipid sticks are shown in the colors illustrated in **Figure 1A**. **(G)** Comparison of the highest  
751 occupancy sites identified with PyLipID (surface) and BDQ from the Cryo-EM structure (PDB:  
752 7JGC) (sticks). **(H)** PMF of BDQ moving through a mycobacterial plasma membrane with the  
753 error shown in grey. A schematic of the PMF is shown as an insert.

754



755

- 756 1. WHO (2022) Global tuberculosis report 2022. (World Health Organization, Geneva).
- 757 2. C. R. Horsburgh, C. E. Barry, C. Lange, Treatment of Tuberculosis. *New England*
- 758 *Journal of Medicine* **373**, 2149-2160 (2015).
- 759 3. WHO (2021) Global Tuberculosis Report 2021. (World Health Organization, Geneva).
- 760 4. WHO (2022) The End TB Strategy.
- 761 5. WHO (2021) 1.4 million with tuberculosis, lost out on treatment during first year of
- 762 COVID-19.
- 763 6. L. Chiaradia *et al.*, Dissecting the mycobacterial cell envelope and defining the
- 764 composition of the native mycomembrane. *Scientific Reports* **7**, 12807 (2017).
- 765 7. C. L. Dulberger, E. J. Rubin, C. C. Boutte, The mycobacterial cell envelope — a moving
- 766 target. *Nature Reviews Microbiology* **18**, 47-59 (2020).
- 767 8. S. M. Batt, D. E. Minnikin, G. S. Besra, The thick waxy coat of mycobacteria, a
- 768 protective layer against antibiotics and the host's immune system. *Biochemical*
- 769 *Journal* **477**, 1983-2006 (2020).
- 770 9. E. Fullam, R. J. Young, Physicochemical properties and Mycobacterium tuberculosis
- 771 transporters: keys to efficacious antitubercular drugs? *RSC Medicinal Chemistry* **12**,
- 772 43-56 (2021).
- 773 10. K. A. Sacksteder, M. Protopopova, C. E. Barry, 3rd, K. Andries, C. A. Nacy, Discovery
- 774 and development of SQ109: a new antitubercular drug with a novel mechanism of
- 775 action. *Future Microbiol* **7**, 823-837 (2012).
- 776 11. Y.-M. Boudehen *et al.*, Mycobacterial resistance to zinc poisoning requires assembly
- 777 of P-ATPase-containing membrane metal efflux platforms. *Nature Communications*
- 778 **13**, 4731 (2022).
- 779 12. J. M. Hayashi *et al.*, Spatially distinct and metabolically active membrane domain in
- 780 mycobacteria. *Proc Natl Acad Sci U S A* **113**, 5400-5405 (2016).
- 781 13. R. Bansal-Mutalik, H. Nikaido, Mycobacterial outer membrane is a lipid bilayer and
- 782 the inner membrane is unusually rich in diacyl phosphatidylinositol dimannosides.
- 783 *Proceedings of the National Academy of Sciences* **111**, 4958-4963 (2014).
- 784 14. M. Gilleron, V. F. J. Quesniaux, G. Puzo, Acylation State of the Phosphatidylinositol
- 785 Hexamannosides from *Mycobacterium bovis* Bacillus Calmette Guérin and
- 786 *Mycobacterium tuberculosis* H37Rv and Its Implication in Toll-like Receptor Response
- 787 *Journal of Biological Chemistry* **278**, 29880-29889 (2003).
- 788 15. M. Gilleron *et al.*, Acylation State of the Phosphatidylinositol Mannosides from
- 789 *Mycobacterium bovis* Bacillus Calmette Guérin and Ability to Induce Granuloma and
- 790 Recruit Natural Killer T Cells. *Journal of Biological Chemistry* **276**, 34896-34904
- 791 (2001).
- 792 16. M. Daffé, H. Marrakchi, Unraveling the Structure of the Mycobacterial Envelope.
- 793 *Microbiol Spectr* **7** (2019).
- 794 17. M. Jackson, The mycobacterial cell envelope-lipids. *Cold Spring Harb Perspect Med* **4**,
- 795 a021105 (2014).
- 796 18. R. Kalscheuer *et al.*, The Mycobacterium tuberculosis capsule: a cell structure with
- 797 key implications in pathogenesis. *Biochemical Journal* **476**, 1995-2016 (2019).
- 798 19. M. E. Guerin, J. Korduláková, P. M. Alzari, P. J. Brennan, M. Jackson, Molecular Basis
- 799 of Phosphatidyl-*myo*-inositol Mannoside Biosynthesis and Regulation in
- 800 Mycobacteria *Journal of Biological Chemistry* **285**, 33577-33583 (2010).

- 801 20. V. Corradi *et al.*, Emerging Diversity in Lipid–Protein Interactions. *Chemical Reviews*  
802 **119**, 5775-5848 (2019).
- 803 21. R. A. Corey *et al.*, Identification and assessment of cardiolipin interactions with E. coli  
804 inner membrane proteins. *Sci Adv* **7** (2021).
- 805 22. H. I. Ingólfsson *et al.*, Lipid Organization of the Plasma Membrane. *Journal of the*  
806 *American Chemical Society* **136**, 14554-14559 (2014).
- 807 23. I. D. Pogozheva *et al.*, Comparative Molecular Dynamics Simulation Studies of  
808 Realistic Eukaryotic, Prokaryotic, and Archaeal Membranes. *Journal of Chemical*  
809 *Information and Modeling* **62**, 1036-1051 (2022).
- 810 24. P. Adhyapak *et al.*, Lipid Clustering in Mycobacterial Cell Envelope Layers Governs  
811 Spatially Resolved Solvation Dynamics. *Chemistry – An Asian Journal* **17**, e202200146  
812 (2022).
- 813 25. H. Guo *et al.*, Structure of mycobacterial ATP synthase bound to the tuberculosis  
814 drug bedaquiline. *Nature* **589**, 143-147 (2021).
- 815 26. P. C. T. Souza *et al.*, Martini 3: a general purpose force field for coarse-grained  
816 molecular dynamics. *Nature Methods* **18**, 382-388 (2021).
- 817 27. R. Alessandri *et al.*, Martini 3 Coarse-Grained Force Field: Small Molecules. *Advanced*  
818 *Theory and Simulations* **5**, 2100391 (2022).
- 819 28. L. Borges-Araújo, P. C. T. Souza, F. Fernandes, M. N. Melo, Improved  
820 Parameterization of Phosphatidylinositide Lipid Headgroups for the Martini 3  
821 Coarse-Grain Force Field. *Journal of Chemical Theory and Computation* **18**, 357-373  
822 (2022).
- 823 29. P. Banerjee, R. Lipowsky, M. Santer, Coarse-Grained Molecular Model for the  
824 Glycosylphosphatidylinositol Anchor with and without Protein. *Journal of Chemical*  
825 *Theory and Computation* **16**, 3889-3903 (2020).
- 826 30. T. A. Wassenaar, H. I. Ingólfsson, R. A. Böckmann, D. P. Tieleman, S. J. Marrink,  
827 Computational Lipidomics with insane: A Versatile Tool for Generating Custom  
828 Membranes for Molecular Simulations. *Journal of Chemical Theory and Computation*  
829 **11**, 2144-2155 (2015).
- 830 31. G. Bussi, D. Donadio, M. Parrinello, Canonical sampling through velocity rescaling. *J*  
831 *Chem Phys* **126**, 014101 (2007).
- 832 32. M. Parrinello, A. Rahman, Polymorphic transitions in single crystals: A new molecular  
833 dynamics method. **52:12** (1981).
- 834 33. M. J. Abraham *et al.*, GROMACS: High performance molecular simulations through  
835 multi-level parallelism from laptops to supercomputers. *SoftwareX* **1-2**, 19-25 (2015).
- 836 34. J. A. Barker, R. O. Watts, Monte Carlo studies of the dielectric properties of water-  
837 like models. *Molecular Physics* **26**, 789-792 (1973).
- 838 35. E. L. Wu, Y. Qi, K. C. Song, J. B. Klauda, W. Im, Preferred Orientations of  
839 Phosphoinositides in Bilayers and Their Implications in Protein Recognition  
840 Mechanisms. *The Journal of Physical Chemistry B* **118**, 4315-4325 (2014).
- 841 36. J. Lee *et al.*, CHARMM-GUI Membrane Builder for Complex Biological Membrane  
842 Simulations with Glycolipids and Lipoglycans. *Journal of Chemical Theory and*  
843 *Computation* **15**, 775-786 (2019).
- 844 37. K. Vanommeslaeghe *et al.*, CHARMM general force field: A force field for drug-like  
845 molecules compatible with the CHARMM all-atom additive biological force fields.  
846 *Journal of computational chemistry* **31**, 671-690 (2010).

- 847 38. J. Huang *et al.*, CHARMM36m: an improved force field for folded and intrinsically  
848 disordered proteins. *Nature Methods* **14**, 71-73 (2017).
- 849 39. E. L. Wu *et al.*, CHARMM-GUI Membrane Builder toward realistic biological  
850 membrane simulations. *Journal of Computational Chemistry* **35**, 1997-2004 (2014).
- 851 40. U. Essmann *et al.*, A smooth particle mesh Ewald method. *The Journal of Chemical*  
852 *Physics* **103**, 8577-8593 (1995).
- 853 41. S.-J. Marrink (2022) Downloads: Lipids.
- 854 42. B. M. Groenewald W, Croft A, Marrink S-J., Molecular Dynamics of Mycolic Acid  
855 Monolayers. *ChemRxiv* (2019).
- 856 43. P. W. Fowler *et al.*, Membrane stiffness is modified by integral membrane proteins.  
857 *Soft Matter* **12**, 7792-7803 (2016).
- 858 44. P. Smith, C. D. Lorenz, LiPyphilic: A Python Toolkit for the Analysis of Lipid Membrane  
859 Simulations. *Journal of Chemical Theory and Computation* **17**, 5907-5919 (2021).
- 860 45. M. Bonomi *et al.*, Promoting transparency and reproducibility in enhanced molecular  
861 simulations. *Nature Methods* **16**, 670-673 (2019).
- 862 46. S. Buchoux, FATSLiM: a fast and robust software to analyze MD simulations of  
863 membranes. *Bioinformatics* **33**, 133-134 (2017).
- 864 47. J. D. Hunter, Matplotlib: A 2D Graphics Environment. *Computing in Science &*  
865 *Engineering* **9**, 90-95 (2007).
- 866 48. C. UniProt, UniProt: the universal protein knowledgebase in 2021. *Nucleic Acids Res*  
867 **49**, D480-D489 (2021).
- 868 49. J. Jumper *et al.*, Highly accurate protein structure prediction with AlphaFold. *Nature*  
869 **596**, 583-589 (2021).
- 870 50. T. Nugent, D. T. Jones, Membrane protein orientation and refinement using a  
871 knowledge-based statistical potential. *BMC Bioinformatics* **14**, 276 (2013).
- 872 51. P. C. Kroon (2020) Aggregate, automate, assemble. . (University of Groningen), pp  
873 16-53.
- 874 52. J. A. Graham, J. W. Essex, S. Khalid, PyCGTOOL: Automated Generation of Coarse-  
875 Grained Molecular Dynamics Models from Atomistic Trajectories. *Journal of*  
876 *Chemical Information and Modeling* **57**, 650-656 (2017).
- 877 53. S. Kim *et al.*, CHARMM-GUI ligand reader and modeler for CHARMM force field  
878 generation of small molecules. *Journal of Computational Chemistry* **38**, 1879-1886  
879 (2017).
- 880 54. N. C. f. B. Information (2022) PubChem Compound Summary for CID 5388906,  
881 Bedaquiline. (National Center for Biotechnology Information).
- 882 55. I. V. Tetko *et al.*, Virtual Computational Chemistry Laboratory – Design and  
883 Description. *Journal of Computer-Aided Molecular Design* **19**, 453-463 (2005).
- 884 56. A. Waterhouse *et al.*, SWISS-MODEL: homology modelling of protein structures and  
885 complexes. *Nucleic Acids Research* **46**, W296-W303 (2018).
- 886 57. F. Sievers *et al.*, Fast, scalable generation of high-quality protein multiple sequence  
887 alignments using Clustal Omega. *Molecular Systems Biology* **7**, 539 (2011).
- 888 58. W. Song *et al.*, PyLipID: A Python Package for Analysis of Protein–Lipid Interactions  
889 from Molecular Dynamics Simulations. *Journal of Chemical Theory and Computation*  
890 **18**, 1188-1201 (2022).
- 891 59. R. A. Corey, O. N. Vickery, M. S. P. Sansom, P. J. Stansfeld, Insights into Membrane  
892 Protein–Lipid Interactions from Free Energy Calculations. *Journal of Chemical Theory*  
893 *and Computation* **15**, 5727-5736 (2019).

- 894 60. M. Souaille, B. t. Roux, Extension to the weighted histogram analysis method:  
895 combining umbrella sampling with free energy calculations. *Computer Physics*  
896 *Communications* **135**, 40-57 (2001).
- 897 61. J. S. Hub, B. L. de Groot, D. van der Spoel, g\_wham—A Free Weighted Histogram  
898 Analysis Implementation Including Robust Error and Autocorrelation Estimates.  
899 *Journal of Chemical Theory and Computation* **6**, 3713-3720 (2010).
- 900 62. P. S. Schmalhorst, F. Deluweit, R. Scherrers, C.-P. Heisenberg, M. Sikora, Overcoming  
901 the Limitations of the MARTINI Force Field in Simulations of Polysaccharides. *Journal*  
902 *of Chemical Theory and Computation* **13**, 5039-5053 (2017).
- 903 63. C. Hoffmann, A. Leis, M. Niederweis, J. M. Plitzko, H. Engelhardt, Disclosure of the  
904 mycobacterial outer membrane: Cryo-electron tomography and vitreous sections  
905 reveal the lipid bilayer structure. *Proceedings of the National Academy of Sciences*  
906 **105**, 3963-3967 (2008).
- 907 64. B. Zuber *et al.*, Direct visualization of the outer membrane of mycobacteria and  
908 corynebacteria in their native state. *J Bacteriol* **190**, 5672-5680 (2008).
- 909 65. P. Adhyapak *et al.*, Dynamical Organization of Compositionally Distinct Inner and  
910 Outer Membrane Lipids of Mycobacteria. *Biophysical Journal* **118**, 1279-1291 (2020).
- 911 66. A. V. Hughes *et al.*, Physical Properties of Bacterial Outer Membrane Models:  
912 Neutron Reflectometry & Molecular Simulation. *Biophysical Journal* **116**, 1095-1104  
913 (2019).
- 914 67. R. Friedman, Membrane-Ion Interactions. *The Journal of membrane biology* **251**,  
915 453-460 (2018).
- 916 68. B. Modak, S. Girkar, R. Narayan, S. Kapoor, Mycobacterial Membranes as Actionable  
917 Targets for Lipid-Centric Therapy in Tuberculosis. *Journal of Medicinal Chemistry* **65**,  
918 3046-3065 (2022).
- 919 69. P. P. Nguyen, T. Kado, M. Prithviraj, M. S. Siegrist, Y. S. Morita, Inositol acylation of  
920 phosphatidylinositol mannosides: a rapid mass response to membrane fluidization in  
921 mycobacteria. *Journal of Lipid Research* **63** (2022).
- 922 70. J. H. Lorent *et al.*, Plasma membranes are asymmetric in lipid unsaturation, packing  
923 and protein shape. *Nat Chem Biol* **16**, 644-652 (2020).
- 924 71. G. von Heijne, Net N-C charge imbalance may be important for signal sequence  
925 function in bacteria. *Journal of Molecular Biology* **192**, 287-290 (1986).
- 926 72. J. A. Baker, W.-C. Wong, B. Eisenhaber, J. Warwicker, F. Eisenhaber, Charged  
927 residues next to transmembrane regions revisited: “Positive-inside rule” is  
928 complemented by the “negative inside depletion/outside enrichment rule”. *BMC*  
929 *Biology* **15**, 66 (2017).
- 930 73. I. D. Pogozheva, S. Tristram-Nagle, H. I. Mosberg, A. L. Lomize, Structural adaptations  
931 of proteins to different biological membranes. *Biochimica et Biophysica Acta (BBA) -*  
932 *Biomembranes* **1828**, 2592-2608 (2013).
- 933 74. R. J. Anderson, P. W. Groundwater, A. Todd, A. J. Worsley, *Antibacterial agents :*  
934 *chemistry, mode of action, mechanisms of resistance and clinical applications* (Wiley-  
935 Blackwell, Chichester, 2012), pp. 378.
- 936 75. V. A. Dartois, E. J. Rubin, Anti-tuberculosis treatment strategies and drug  
937 development: challenges and priorities. *Nature Reviews Microbiology*  
938 10.1038/s41579-022-00731-y (2022).

- 939 76. A. Krah, G. Grüber, P. J. Bond, Binding properties of the anti-TB drugs bedaquiline  
940 and TBAJ-876 to a mycobacterial F-ATP synthase. *Current Research in Structural*  
941 *Biology* **4**, 278-284 (2022).
- 942 77. F. Bardou, C. Raynaud, C. Ramos, M. A. Lanéelle, G. Lanéelle, Mechanism of isoniazid  
943 uptake in Mycobacterium tuberculosis. *Microbiology* **144**, 2539-2544 (1998).
- 944 78. A. N. Unissa, S. Subbian, L. E. Hanna, N. Selvakumar, Overview on mechanisms of  
945 isoniazid action and resistance in Mycobacterium tuberculosis. *Infection, Genetics*  
946 *and Evolution* **45**, 474-492 (2016).
- 947 79. M. Jackson *et al.*, Inactivation of the antigen 85C gene profoundly affects the  
948 mycolate content and alters the permeability of the Mycobacterium tuberculosis cell  
949 envelope. *Molecular Microbiology* **31**, 1573-1587 (1999).
- 950 80. A. L. Duncan, A. J. Robinson, J. E. Walker, Cardiolipin binds selectively but transiently  
951 to conserved lysine residues in the rotor of metazoan ATP synthases. *Proceedings of*  
952 *the National Academy of Sciences* **113**, 8687-8692 (2016).
- 953 81. R. A. Corey, P. J. Stansfeld, M. S. P. Sansom, The energetics of protein-lipid  
954 interactions as viewed by molecular simulations. *Biochem Soc Trans* **48**, 25-37  
955 (2020).
- 956 82. J. Briffotiaux, W. Huang, X. Wang, B. Gicquel, MmpS5/MmpL5 as an efflux pump in  
957 Mycobacterium species. *Tuberculosis* **107**, 13-19 (2017).
- 958 83. G. Degiacomi *et al.*, In vitro Study of Bedaquiline Resistance in Mycobacterium  
959 tuberculosis Multi-Drug Resistant Clinical Isolates. *Frontiers in Microbiology* **11**  
960 (2020).
- 961 84. R. J. Clarke, K. R. Hossain, K. Cao, Physiological roles of transverse lipid asymmetry of  
962 animal membranes. *Biochimica et Biophysica Acta (BBA) - Biomembranes* **1862**,  
963 183382 (2020).
- 964 85. W. Im, S. Khalid, Molecular Simulations of Gram-Negative Bacterial Membranes  
965 Come of Age. *Annual Review of Physical Chemistry* **71**, 171-188 (2020).
- 966 86. J. Augenreich *et al.*, The conical shape of DIM lipids promotes Mycobacterium  
967 tuberculosis infection of macrophages. *Proceedings of the National Academy of*  
968 *Sciences* **116**, 25649-25658 (2019).
- 969 87. A. Queiroz, L. W. Riley, Bacterial immunostat: Mycobacterium tuberculosis lipids and  
970 their role in the host immune response. *Rev Soc Bras Med Trop* **50**, 9-18 (2017).
- 971 88. K. A. Abrahams, G. S. Besra, Synthesis and recycling of the mycobacterial cell  
972 envelope. *Current Opinion in Microbiology* **60**, 58-65 (2021).
- 973